Catalyst
Slingshot members are tracking this event:
FDA Designated Juno's JCAR017 a Breakthrough Therapy for the Treatment of Relapsed/Refractory Aggressive Large B-cell Non-Hodgkin Lymphoma (NHL), Including Diffuse Large B-Cell Lymphoma (DLBCL) and Certain Other Lymphomas
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| JUNO |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 20, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Jcar017, Breakthrough Therapy Status, Relapsed/refractory, Aggressive Large B-cell, Non-hodgkin Lymphoma, Nhl, Diffuse Large B-cell Lymphoma, Dlbcl, Lymphomas
